Anteris Technologies Showcases the DurAVR® THV Results
MINNEAPOLIS and BRISBANE, Australia — Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has made significant strides with the release of 30-day clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV), evaluated among one hundred patients suffering from severe aortic stenosis. The innovative valve was examined specifically in patients with small aortic annuli, showcasing remarkable safety and efficacy.
Clinical Significance of the DurAVR® THV
The findings were presented at the prestigious PCR London Valves conference by Prof. Dr. Ole De Backer, coinciding with the publication in the journal EuroIntervention. The clinical data highlighted a remarkable achievement: the DurAVR® THV exhibited single-digit mean gradients, showcasing a favorable hemodynamic profile with no valve-related mortality or significant paravalvular leaks. Impressively, the study revealed that 97% of patients avoided moderate to severe prosthesis-patient mismatch (PPM), lending credibility to the valve's effectiveness.
Key Highlights from the 30-Day Results
The DurAVR® THV demonstrated a large effective orifice area (EOA) with a mean pressure gradient of just 8.2 mmHg. Additionally, the positive safety outcomes included:
- No reported valve-related mortalities within the 30-day timeframe.
- Zero instances of moderate or severe paravalvular leak (PVL).
- A notably low rate of prosthesis-patient mismatch, which stood at only 3.0%, a drastic improvement over standards reported for conventional devices.
- A technical success rate benchmarked at 100% for the last fifty patients included in the study.
Expert Insights on DurAVR® THV
Prof. Dr. De Backer commented on the importance of these results, stating, "The DurAVR® THV showcased impressive technical and device success rates alongside promising 30-day hemodynamic outcomes. The low incidences of PPM underline the device’s potential for patients with small annuli." This perspective is crucial as PPM has been linked to reduced longevity and can heighten the risk of valve degeneration.
Chris Meduri, M.D., the Chief Medical Officer at Anteris, emphasized the impact of achieving a 97% freedom from moderate or severe PPM, particularly vital for patients with small aortic annuli. Such a finding reinforces the clinical relevance of their research and development efforts.
Future Prospects of the DurAVR® THV
This analysis encompassed data from the ongoing EMBARK study and preliminary feasibility studies across the United States and Europe. It aims to establish a clinical comparison with existing therapies like transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis.
Wayne Paterson, the Vice Chairman and CEO, noted, "The consistent clinical profiles emerging from the 30-day and 1-year outcomes solidify our anticipation for the ongoing PARADIGM Trial." This trial serves as a pivotal progression in evaluating the DurAVR® THV compared to current commercial TAVRs. Paterson's insights provoke optimism regarding the path toward commercialization of the DurAVR® technology which may transform treatments for patients with life-threatening valve conditions.
About Anteris Technologies
Anteris Technologies Global Corp. is at the forefront of the structural heart device sector, dedicated to the innovation of medical devices aimed at restoring optimal heart functionality. Established in Australia with a robust base in Minneapolis, Anteris prides itself on adopting a science-driven approach underpinned by a diverse team of experts committed to changing lives.
Innovative Heart Valve Technology
The DurAVR® THV is the first biomimetic transcatheter heart valve designed by collaborating closely with eminent interventional cardiologists and cardiac surgeons. Its unique characteristics mimic a healthy aortic valve, facilitating normal blood flow dynamics while employing Anteris’ patented ADAPT® tissue technology, renowned for its anti-calcification properties.
Frequently Asked Questions
What is the DurAVR® THV?
The DurAVR® THV is a novel transcatheter heart valve designed to treat severe aortic stenosis, particularly for patients with small aortic annuli.
What were the significant outcomes of the recent study?
Outcomes included low mean pressure gradients, a high technical success rate, and minimal instances of prosthesis-patient mismatch.
Why is PPM significant in heart valve treatments?
Prosthesis-patient mismatch can lead to increased risks of valve failure and negatively impact patient's health and longevity.
How does DurAVR® compare with traditional valves?
DurAVR® showcases enhanced hemodynamic outcomes and lower rates of complications compared to conventional transcatheter valves.
What is Anteris's vision for the future?
Anteris aims to advance the commercialization of cardiovascular technologies that provide significant health benefits and improve patient outcomes.
